- Home
- PCSA vs WINT Comparison
PCSA vs WINT Comparison
Compare PCSA & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- WINT
- Stock Information
- Founded
- PCSA 2011
- WINT 1992
- Country
- PCSA United States
- WINT United States
- Employees
- PCSA 13
- WINT N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCSA Health Care
- WINT Health Care
- Exchange
- PCSA Nasdaq
- WINT Nasdaq
- Market Cap
- PCSA 1.2M
- WINT 996.6K
- IPO Year
- PCSA N/A
- WINT 1995
- Fundamental
- Price
- PCSA $0.24
- WINT $1.22
- Analyst Decision
- PCSA Strong Buy
- WINT Hold
- Analyst Count
- PCSA 1
- WINT 1
- Target Price
- PCSA $6.00
- WINT $350.00
- AVG Volume (30 Days)
- PCSA 6.0M
- WINT 359.4K
- Earning Date
- PCSA 05-09-2025
- WINT 05-06-2025
- Dividend Yield
- PCSA N/A
- WINT N/A
- EPS Growth
- PCSA N/A
- WINT N/A
- EPS
- PCSA N/A
- WINT N/A
- Revenue
- PCSA N/A
- WINT N/A
- Revenue This Year
- PCSA N/A
- WINT N/A
- Revenue Next Year
- PCSA N/A
- WINT N/A
- P/E Ratio
- PCSA N/A
- WINT N/A
- Revenue Growth
- PCSA N/A
- WINT N/A
- 52 Week Low
- PCSA $0.22
- WINT $1.01
- 52 Week High
- PCSA $3.10
- WINT $737.50
- Technical
- Relative Strength Index (RSI)
- PCSA 32.49
- WINT 33.12
- Support Level
- PCSA $0.20
- WINT $1.01
- Resistance Level
- PCSA $0.25
- WINT $1.19
- Average True Range (ATR)
- PCSA 0.06
- WINT 0.14
- MACD
- PCSA 0.01
- WINT 0.11
- Stochastic Oscillator
- PCSA 32.69
- WINT 31.25
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.